Sponsor or institution

Clinical trials and research at AstraZeneca

• 244Clinical trials
• 3New in 30 days
• 81Countries

Newest trials

All recruiting trials (newest 150 of 244)

• Understanding the disease burden of hypophosphatasia in Chinese patients

  This study tests how hypophosphatasia affects people in China by collecting real-world data on symptoms, quality of life, and costs.

  Recruiting AstraZeneca · Beijing and 21 other locations · NCT07905287

• Real-world use of selumetinib for adult NF1 with inoperable plexiform neurofibromas

  This registry-following study tests how well and safely selumetinib works in adults with NF1 who have symptomatic, inoperable PN.

  Recruiting AstraZeneca · Beijing and 25 other locations · NCT07888517

• Durvalumab with FLOT before and after surgery for resectable gastric/GEJ cancer in Chinese patients

  This trial tests whether adding durvalumab to FLOT chemotherapy before and after surgery helps Chinese patients with resectable gastric or gastroesophageal junction cancer.

  Recruiting at 11 sites Phase 3 AstraZeneca · Beijing and 40 other locations · NCT07877818

• Torvutatug samrotecan plus bevacizumab as first-line maintenance in non-HRD advanced epithelial ovarian cancer

  This trial tests whether adding torvu-samrotecan to bevacizumab after standard chemotherapy helps people with non-HRD advanced epithelial ovarian cancer live longer without the cancer worsening compared with bevacizumab alone.

  Recruiting at 4 sites Phase 3 AstraZeneca · Tamarac, Florida and 219 other locations · NCT07851025

• AZD0543 safety and PK in healthy adults

  This study tests whether AZD0543 is safe and how it behaves in the body compared with a placebo in healthy adults age 18–55.

  Recruiting at 2 sites Phase 1 AstraZeneca · Los Alamitos, California and 1 other locations · NCT07824622

• Torvutatug samrotecan with or without bevacizumab as maintenance in platinum-sensitive relapsed epithelial ovarian, fallopian tube, or primary peritoneal cancer

  This study tests torvutatug samrotecan, with or without bevacizumab, to see if it helps people with platinum-sensitive relapsed ovarian, fallopian tube, or primary peritoneal cancer stay cancer-free longer after their last platinum therapy.

  Recruiting at 3 sites Phase 3 AstraZeneca · Anchorage, Alaska and 123 other locations · NCT07816666

• Observational look at how adults with stomach and GEJ cancer are diagnosed and treated in Greece

  This study will look at real-world care for adults with stage II-IVB gastric or gastroesophageal junction cancer in Greece to see how they are diagnosed and managed in usual practice.

  Recruiting at 3 sites AstraZeneca · Alexandroupoli and 8 other locations · NCT07800754

• AZD6234: a new weekly shot to help adults lose weight

  This Phase 3 trial tests whether AZD6234 helps adults with obesity or overweight and weight-related health issues lose weight compared to placebo.

  Recruiting at 76 sites Phase 3 AstraZeneca · Dothan, Alabama and 219 other locations · NCT07784725

• AZD6234: a new option for adults with type 2 diabetes and excess weight

  A phase 3 trial tests whether AZD6234 helps adults with type 2 diabetes and overweight or obesity more than placebo over about 68 weeks.

  Recruiting at 58 sites Phase 3 AstraZeneca · Fairhope, Alabama and 229 other locations · NCT07784270

• Glomerulonephritis Kidney Transplant Recipient Cohort (China)

  This study will follow adults with glomerulonephritis who are scheduled for kidney transplant in China to see how GN recurs after transplant and how the primary disease progresses over 3 years.

  Recruiting AstraZeneca · Beijing, Beijing Municipality and 8 other locations · NCT07783737

• AZD6234 added to current diabetes therapy to help with weight loss in adults who are overweight or have obesity

  This study tests whether AZD6234, when added to a person’s current incretin-based weight management therapy, can help adults with obesity or overweight lose more weight than a placebo over about 68 weeks.

  Recruiting at 56 sites Phase 3 AstraZeneca · Escondido, California and 95 other locations · NCT07776509

• Elecoglipron in adults who are overweight or obese with or without type 2 diabetes

  This study tests whether an oral drug called elecoglipron can help adults lose weight when added to diet and exercise, compared with a placebo.

  Recruiting at 40 sites Phase 3 AstraZeneca · Baotou and 48 other locations · NCT07775404

• AZD0292 for bronchiectasis with chronic Pseudomonas colonization

  This Phase 2 study tests whether AZD0292 given by IV can reduce exacerbations in Chinese adults with bronchiectasis who are chronically colonized with Pseudomonas aeruginosa.

  Recruiting at 40 sites Phase 2 AstraZeneca · Anyang and 39 other locations · NCT07774403

• AZD0120 added to induction in multiple myeloma patients ineligible for stem cell transplant

  In people with newly diagnosed multiple myeloma who can’t have a stem cell transplant, this study tests whether a single dose of AZD0120 after standard induction therapy helps more than continuing the standard therapy.

  Recruiting Phase 3 AstraZeneca · Gilbert, Arizona and 123 other locations · NCT07764978

• Elecoglipron vs placebo for adults with HFpEF or HFmrEF

  This Phase 3 study tests whether elecoglipron helps people with HFpEF or HFmrEF who are on dapagliflozin and standard care.

  Recruiting at 24 sites Phase 3 AstraZeneca · Fairhope, Alabama and 678 other locations · NCT07761117

• Elecoglipron vs. placebo in adults with chronic kidney disease

  This Phase 3 trial tests whether elecoglipron helps adults with CKD, with or without type 2 diabetes, who are already on a stable SGLT2 inhibitor and standard kidney-care treatment.

  Recruiting at 14 sites Phase 3 AstraZeneca · Huntsville, Alabama and 714 other locations · NCT07753993

• Anifrolumab in Chinese patients with active moderate-to-severe SLE

  This study tests whether adding anifrolumab to standard care helps Chinese adults with active moderate-to-severe SLE achieve remission and reduces glucocorticoid use.

  Recruiting at 25 sites Phase 3 AstraZeneca · Beijing and 73 other locations · NCT07751848

• Observational look at treatment patterns and outcomes in HR-positive, HER2-negative metastatic breast cancer in China

  This real-world study tests how patients with HR+/HER2- metastatic breast cancer in China are treated and how they fare over time.

  Recruiting AstraZeneca · Nanjing, Jiangsu · NCT07743944

• AZD0120 consolidation vs ASCT in transplant-eligible newly diagnosed multiple myeloma

  This study tests whether AZD0120 given as consolidation can work as well as or better than traditional autologous stem cell transplant in transplant-eligible patients with newly diagnosed multiple myeloma.

  Recruiting at 2 sites Phase 3 AstraZeneca · Gilbert, Arizona and 113 other locations · NCT07735637

• Elecoglipron in healthy people: comparing different oral forms

  This early study tests whether several oral formulations of elecoglipron are absorbed safely in healthy adults.

  Recruiting at 2 sites Phase 1 AstraZeneca · Glendale, California and 1 other locations · NCT07723833

• Dato-DXd plus rilvegostomig after high-risk MIUC surgery

  This study tests whether Dato-DXd plus rilvegostomig can improve outcomes after high-risk bladder/upper tract urothelial cancer surgery compared with standard care.

  Recruiting at 3 sites Phase 3 AstraZeneca · Hot Springs, Arkansas and 159 other locations · NCT07720284

• Guideline-Directed Medical Therapy to Help Uncontrolled Asthma on ICS-LABA

  This study tests whether following a GDMT pathway can improve asthma control in adults with uncontrolled asthma who are on medium- to high-dose ICS-LABA.

  Recruiting AstraZeneca · Chengdu and 19 other locations · NCT07718724

• Saruparib plus physician’s ARPI choice vs placebo in men with metastatic hormone-sensitive prostate cancer previously treated with docetaxel or Lu-PSMA

  This study tests whether adding saruparib to a physician’s choice of ARPI helps men with metastatic hormone-sensitive prostate cancer who have already had docetaxel or Lu-PSMA therapy and no progression, compared with placebo plus ARPI.

  Recruiting at 6 sites Phase 3 AstraZeneca · Hot Springs, Arkansas and 209 other locations · NCT07711002

• Keeping you on anifrolumab after a positive finish with your prior study

  This study lets people who finished a prior anifrolumab trial and still benefit continue receiving the medicine to see if it stays safe and tolerable for them.

  Recruiting at 4 sites Phase 3 AstraZeneca · Phoenix, Arizona and 165 other locations · NCT07691970

• Ocular Imaging to help detect ATTR-CM in adults with heart failure

  This multicenter pilot study tests whether eye imaging can help distinguish people with transthyretin amyloid cardiomyopathy from other heart failure patients.

  Recruiting AstraZeneca · Palo Alto, California and 19 other locations · NCT07690436

• Baxdrostat for Uncontrolled Hypertension in Chinese Adults

  This study tests whether baxdrostat 2 mg once daily can lower 24-hour systolic blood pressure in adults with uncontrolled hypertension who are already on multiple hypertension medications.

  Recruiting Phase 3 AstraZeneca · Beijing and 50 other locations · NCT07686120

• AZD4045 in Relapsed or Refractory Multiple Myeloma

  This study tests AZD4045 alone and with daratumumab and aldesleukin in adults whose multiple myeloma has returned or stopped responding to treatment.

  Recruiting at 3 sites Phase 1/2 AstraZeneca · Duarte, California and 11 other locations · NCT07681596

• Elecoglipron for weight management in adults with obesity or overweight with or without type 2 diabetes

  This study tests whether taking elecoglipron once daily helps adults with obesity or overweight, with or without type 2 diabetes, lose more weight than placebo when combined with diet and exercise.

  Recruiting at 220 sites Phase 3 AstraZeneca · Birmingham, Alabama and 324 other locations · NCT07667803

• Elecoglipron plus background insulin in adults with type 2 diabetes

  This study tests whether adding Elecoglipron to existing insulin therapy helps adults with type 2 diabetes manage their blood sugar better than a placebo.

  Recruiting at 6 sites Phase 3 AstraZeneca · Little Rock, Arkansas and 131 other locations · NCT07664553

• Development of endotype-based biomarkers to guide care for CRSwNP patients

  This study tests whether inflammatory endotypes can be used to tailor treatment for adults with chronic rhinosinusitis with or without nasal polyps in Greece.

  Recruiting AstraZeneca · Alexandroupoli and 3 other locations · NCT07663409

• Can Elecoglipron help adults with type 2 diabetes compared with an existing medicine called semaglutide?

  This study tests whether the pill Elecoglipron works as well as oral semaglutide in adults with type 2 diabetes who have added heart risk factors.

  Recruiting at 107 sites Phase 3 AstraZeneca · Birmingham, Alabama and 209 other locations · NCT07662213

• Elecoglipron vs placebo for adults with type 2 diabetes and impaired kidney function on dapagliflozin

  This study tests whether elecoglipron can help adults with type 2 diabetes and kidney impairment who are taking or may take an SGLT2 inhibitor called dapagliflozin, in addition to their other diabetes medicines.

  Recruiting at 19 sites Phase 3 AstraZeneca · Sun City, Arizona and 185 other locations · NCT07662135

• Combination therapy of Elecoglipron and Dapagliflozin in adults with type 2 diabetes

  This trial tests whether the combination of Elecoglipron and Dapagliflozin works better than each drug alone to improve blood sugar control in adults with type 2 diabetes.

  Recruiting at 116 sites Phase 3 AstraZeneca · Huntsville, Alabama and 302 other locations · NCT07662109

• Elecoglipron with or without dapagliflozin in adults with type 2 diabetes

  This study tests whether elecoglipron, alone or with dapagliflozin, helps adults with type 2 diabetes better control blood sugar than a placebo.

  Recruiting at 2 sites Phase 3 AstraZeneca · Birmingham, Alabama and 148 other locations · NCT07662044

• Long-term safety of eplontersen in adults with transthyretin amyloidosis, including those with prior liver transplant or severe liver impairment

  This study will see if eplontersen remains safe over time for adults with transthyretin amyloidosis, including people who have had a liver transplant or have severe liver problems.

  Recruiting at 6 sites AstraZeneca · Los Angeles, California and 5 other locations · NCT07654855

• AZD8965 in IPF: see if three doses help IPF patients

  This Phase IIb study tests three doses of AZD8965 against placebo in people with idiopathic pulmonary fibrosis, including those who are and aren’t on antifibrotic therapy.

  Recruiting at 103 sites Phase 2 AstraZeneca · Birmingham, Alabama and 197 other locations · NCT07652658

• Hepatocellular Carcinoma Patient Registry (CHARM Hepatocellular Carcinoma MEA)

  This observational study collects medical records of adults with hepatocellular carcinoma to understand how the disease presents and progresses across regions in the Middle East and North Africa.

  Recruiting AstraZeneca · Al Mansurah and 16 other locations · NCT07650773

• Camizestrant plus ribociclib in ER-positive, HER2-negative advanced breast cancer

  This trial tests whether camizestrant plus ribociclib can help people with ER-positive, HER2-negative metastatic breast cancer who have not yet had systemic therapy for advanced disease.

  Recruiting at 4 sites Phase 3 AstraZeneca · Duarte, California and 88 other locations · NCT07647328

• Natural history of BAG3-related dilated cardiomyopathy in Chinese adults

  This is an observational study in Chinese adults with BAG3-related dilated cardiomyopathy to describe how the disease progresses over time.

  Recruiting AstraZeneca · Beijing and 2 other locations · NCT07646600

• Tezepelumab in real-world CRSwNP: a real-world look at patient outcomes

  This study tests tezepelumab in adults with chronic rhinosinusitis with nasal polyps to see how their symptoms and daily life change in routine care over about two years.

  Recruiting at 19 sites AstraZeneca · Berlin and 18 other locations · NCT07633158

• Subcutaneous anifrolumab in children with systemic lupus erythematosus

  This study tests whether subcutaneous anifrolumab is safe and how it behaves in the body for kids with moderate to severe SLE already on standard care.

  Recruiting at 2 sites Phase 2 AstraZeneca · Nedlands and 38 other locations · NCT07630714

• TROP2 NMR Concordance in Advanced NSCLC

  This study tests whether three TROP2 NMR testing solutions (Reference, Local, and Mixed) give the same results in untreated advanced NSCLC patients.

  Recruiting AstraZeneca · Beijing, Beijing Municipality and 3 other locations · NCT07624318

• Balcinrenone plus dapagliflozin vs dapagliflozin alone in CKD stages 3b-4

  This study tests whether balcinrenone combined with dapagliflozin works better than dapagliflozin alone in adults with CKD stage 3b–4.

  Recruiting at 33 sites Phase 3 AstraZeneca · Huntsville, Alabama and 477 other locations · NCT07624305

• A new combination pill to lower LDL cholesterol in adults who haven’t taken cholesterol medicine before

  This study tests whether a fixed-dose combo pill of laroprovstat and rosuvastatin can lower LDL-C better than laroprovstat alone, rosuvastatin alone, or placebo in adults without prior lipid therapy.

  Recruiting at 12 sites Phase 3 AstraZeneca · Dothan, Alabama and 151 other locations · NCT07619131

• Fixed-dose combination of laroprovstat/rosuvastatin vs rosuvastatin alone for high cholesterol

  This study tests whether a fixed-dose combo pill of laroprovstat and rosuvastatin lowers LDL cholesterol better than rosuvastatin alone in adults with high cholesterol who have or are at risk for cardiovascular disease.

  Recruiting at 16 sites Phase 3 AstraZeneca · Sun City West, Arizona and 44 other locations · NCT07619118

• MET Concordance and Gene Profiling in First-Line NSCLC in Genomet

  This study tests how closely four test methods agree with a reference MET assay in adults with untreated non-small cell lung cancer.

  Recruiting at 50 sites AstraZeneca · Anyang and 50 other locations · NCT07613424

• AZD2265 plus standard care vs standard care in PSMA-positive metastatic castration-resistant prostate cancer

  Aims to see if AZD2265 can extend radiographic progression-free survival and overall survival compared with standard treatments for men with PSMA-positive metastatic castration-resistant prostate cancer.

  Recruiting at 19 sites Phase 3 AstraZeneca · Dothan, Alabama and 150 other locations · NCT07611110

• AZD2389 safety and dosing in adults with fatty liver disease and advanced liver scarring

  This study tests whether AZD2389 is safe and how it behaves in adults with steatotic liver disease and advanced fibrosis, comparing it to placebo over about six months.

  Recruiting at 22 sites Phase 2 AstraZeneca · Chandler, Arizona and 21 other locations · NCT07610837

• STRIDE combination in advanced liver cancer: a first-line look at tremelimumab plus durvalumab

  This study tests tremelimumab plus durvalumab as a first-line treatment in adults with advanced or unresectable hepatocellular carcinoma to see how it affects liver health, quality of life, effectiveness, and safety.

  Recruiting at 17 sites AstraZeneca · Ancona and 23 other locations · NCT07607769

• People with type 2 diabetes who may join future diabetes studies

  This study looks to identify adults with type 2 diabetes who might participate in ongoing or future diabetes trials and to see how their current diabetes medicines are used across different regions.

  Recruiting at 19 sites AstraZeneca · Peoria, Arizona and 75 other locations · NCT07606066

• BEYOND: Real-world use of Trastuzumab Deruxtecan in HR-positive, HER2-low/ultralow metastatic breast cancer

  This study tests how Trastuzumab Deruxtecan works in real-world patients with HR-positive, HER2-low or ultralow metastatic breast cancer who have previously had endocrine therapy.

  Recruiting AstraZeneca · Muscat and 8 other locations · NCT07597993

• Adjuvant EGFR-TKI in resected EGFR-mutated NSCLC in China

  This study looks at real-world outcomes in about 2,000 adults with early-stage EGFR-mutated NSCLC who had surgery and then used an EGFR-TKI, using past records and ongoing follow-up in China.

  Recruiting AstraZeneca · Beijing and 13 other locations · NCT07593248

• HER2+ Metastatic Breast Cancer in Kazakhstan (observational)

  This study tests how patients with HER2-positive metastatic breast cancer who are receiving anti-HER2 therapy fare across several Kazakh centers.

  Recruiting at 10 sites AstraZeneca · Oral, Kazakhstan and 11 other locations · NCT07593196

• Combined treatment approach in metastatic prostate cancer using AZD2265 (FPI-2265) with palacaparib or docetaxel

  This study tests how AZD2265 (FPI-2265) with or without palacaparib or docetaxel works in men with metastatic castration-resistant prostate cancer who have already tried AR pathway inhibitors.

  Recruiting at 3 sites Phase 1/2 AstraZeneca · Duarte, California and 37 other locations · NCT07590934

• Surovatamig for adults with anti‑PLA2R primary membranous nephropathy

  This study will test whether subcutaneous surovatamig is safe and can reduce heavy proteinuria in adults with anti‑PLA2R–positive primary membranous nephropathy.

  Recruiting Phase 2 AstraZeneca · Los Angeles, California and 26 other locations · NCT07571746

• Breztri real-world safety and effectiveness in Korean patients with COPD or asthma

  This post-marketing study tests Breztri in real-world Korean patients with COPD or asthma to see how safe it is and how well it works when used as usual care.

  Recruiting at 4 sites AstraZeneca · Chuncheon and 9 other locations · NCT07570394

• Long-term safety of Tozorakimab in COPD patients with prior exacerbations

  This study tests two long-term dosing regimens of tozorakimab in people with COPD who have a history of flare-ups and who completed earlier studies.

  Recruiting at 5 sites Phase 3 AstraZeneca · Aix-en-Provence and 12 other locations · NCT07566195

• How liver impairment affects AZD9550 and AZD6234

  This trial will test how single subcutaneous doses of two investigational drugs, AZD9550 and AZD6234, are processed and tolerated in adults with moderate or severe liver impairment compared with matched healthy volunteers.

  Recruiting at 3 sites Phase 1 AstraZeneca · Chandler, Arizona and 3 other locations · NCT07546760

• Barriers and facilitators to sticking with osimertinib after early-stage NSCLC

  This study asks how adults with early-stage NSCLC in China continue or stop adjuvant osimertinib, by talking with patients and doctors to understand what helps or hinders persistence.

  Recruiting AstraZeneca · Beijing · NCT07542210

• First-in-human AZD8359 STEAP2 TCE in metastatic prostate cancer

  A new treatment called AZD8359 is being tested to see if it is safe and possibly helpful for people with metastatic prostate cancer.

  Recruiting at 5 sites Phase 1/2 AstraZeneca · Orlando, Florida and 7 other locations · NCT07529717

• Two doses of inhaled glycopyrronium added to BFF for children 4 to less than 12 with asthma

  This trial will test whether adding one of two doses of inhaled glycopyrronium to BFF improves lung function in children aged 4 to less than 12 who have asthma.

  Recruiting at 20 sites Phase 2 AstraZeneca · Bakersfield, California and 43 other locations · NCT07525375

• Tezepelumab for Chinese adults with nasal polyps: a 24-week treatment study

  This trial tests whether tezepelumab can improve nasal polyps and symptoms in Chinese adults with chronic rhinosinusitis with nasal polyps who are starting therapy.

  Recruiting at 34 sites Phase 3 AstraZeneca · Beijing and 33 other locations · NCT07520162

• Bronchodilation Test with Portable Oscillometry for Asthma Diagnosis

  This study tests whether a portable oscillometry bronchodilation test can better help diagnose asthma in adults with suspected asthma compared with current tests.

  Recruiting at 17 sites AstraZeneca · Beijing and 23 other locations · NCT07516184

• AZD1043 safety and dosing in adults with overweight or obesity

  This will test the safety and how the body handles AZD1043 in adults living with overweight or obesity.

  Recruiting at 2 sites Phase 1 AstraZeneca · Glendale, California and 2 other locations · NCT07511205

• Surovatamig as consolidation therapy after initial treatment for CLL/SLL with unmutated IGHV

  This study tests whether adding Surovatamig as a maintenance-like consolidation after initial therapy helps people with CLL or SLL with unmutated IGHV.

  Recruiting at 22 sites Phase 3 AstraZeneca · La Jolla, California and 43 other locations · NCT07509151

• Prospective multicenter observational registry for chronic kidney disease in China

  This registry will collect health and treatment data from adults with chronic kidney disease in China to see how therapies, clinical practice, and cardiorenal outcomes vary over time.

  Recruiting at 54 sites AstraZeneca · Anning, Yunnan - South Region and 58 other locations · NCT07481526

• Danicopan added to ravulizumab or eculizumab for PNH in Korea

  This will see if adding Danicopan to ravulizumab or eculizumab is safe and helps people with PNH who are treated in routine care in Korea.

  Recruiting at 3 sites AstraZeneca · Busan and 3 other locations · NCT07457151

• AZD4956 alone or with saruparib for advanced HRR-deficient solid tumors

  This will test AZD4956 by itself and together with saruparib in people who have advanced or metastatic solid tumors with homologous recombination repair defects.

  Recruiting at 14 sites Phase 1/2 AstraZeneca · New York, New York and 18 other locations · NCT07446855

• Continued benralizumab for participants who completed a prior benralizumab study

  This trial tests continuing benralizumab in people who benefited from it in a previous study, to see if long-term treatment is safe and tolerable.

  Recruiting at 20 sites Phase 3 AstraZeneca · Aurora, Colorado and 45 other locations · NCT07444567

• Sonesitatug vedotin plus capecitabine, with or without rilvegostomig, for CLDN18.2-positive advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma

  This trial will test whether adding sonesitatug vedotin to capecitabine, with or without rilvegostomig, helps people with untreated CLDN18.2-positive, HER2-negative advanced or metastatic gastric, GEJ, or esophageal adenocarcinoma.

  Recruiting at 158 sites Phase 3 AstraZeneca · Birmingham, Alabama and 313 other locations · NCT07431281

• Weekly subcutaneous anifrolumab added to antimalarial for people with lupus who are immunosuppressant- and biologic-naïve

  This trial tests whether once-weekly 120 mg subcutaneous anifrolumab plus antimalarial (with or without steroids) helps adults with lupus who have not used immunosuppressants or biologics reach remission and come off long-term steroids.

  Recruiting at 50 sites Phase 3 AstraZeneca · Anniston, Alabama and 107 other locations · NCT07430306

• Camizestrant plus atirmociclib in ER-positive, HER2-negative advanced breast cancer

  This study tests whether combining camizestrant with atirmociclib is safe and tolerable in women whose ER-positive, HER2-negative advanced breast cancer progressed after a CDK4/6 inhibitor.

  Recruiting at 6 sites Phase 2 AstraZeneca · St Louis, Missouri and 5 other locations · NCT07427394

• Disease activity and quality of life in adults with SLE starting subcutaneous anifrolumab

  This project will try to see how subcutaneous anifrolumab works for adults with lupus by collecting clinical measurements and patient-reported outcomes in routine care.

  Recruiting at 21 sites AstraZeneca · Altenburg and 20 other locations · NCT07424261

• CHOICE — what influences EGFR‑TKI treatment decisions for Chinese patients with stage IV non‑small cell lung cancer

  This project uses surveys to see what features of first‑line EGFR‑TKI treatments patients and doctors in China prefer when choosing care for people with stage IV non‑small cell lung cancer.

  Recruiting AstraZeneca · Chengdu · NCT07413757

• Comparing HER2 test results and readings across labs for Chinese patients with NSCLC, gynecologic, biliary tract, or urothelial cancers

  This project will test how well different HER2 lab tests and pathologist readings agree for people in China with NSCLC, certain gynecologic cancers, biliary tract cancer, or urothelial cancer using archived tumor samples.

  Recruiting at 2 sites AstraZeneca · Beijing and 13 other locations · NCT07404202

• AZD5335 given with itraconazole for ovarian, fallopian tube, and primary peritoneal cancer

  This trial will test whether the antifungal itraconazole changes how the investigational drug AZD5335 is processed in the body for people with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.

  Recruiting at 6 sites Phase 1 AstraZeneca · Batumi and 8 other locations · NCT07402915

• Ravulizumab Outcomes in Polish Patients with aHUS

  This observational study in Poland follows patients with atypical hemolytic uremic syndrome who are treated with ravulizumab to see how they do over time in real-world clinical care.

  Recruiting at 5 sites AstraZeneca · Gdansk and 9 other locations · NCT07399730

• Real-world use of tezepelumab for chronic rhinosinusitis with nasal polyps in Russia

  This study will see how tezepelumab works in adults in Russia who have chronic rhinosinusitis with nasal polyps, with or without asthma.

  Recruiting at 10 sites AstraZeneca · Kazan' and 9 other locations · NCT07399665

• Subcutaneous durvalumab plus hyaluronidase dose-finding and safety for solid tumors

  This study will test whether a subcutaneous (under-the-skin) injection of durvalumab with hyaluronidase gives similar blood levels and is safe for people with certain advanced solid tumors, including unresectable liver cancer and specific forms of lung cancer.

  Recruiting at 14 sites Phase 1 AstraZeneca · Fitzroy and 18 other locations · NCT07391670

• AZD0120 dual-target CAR-T (BCMA and CD19) versus standard treatments for relapsed refractory multiple myeloma

  This trial tests whether a dual-target CAR-T therapy called AZD0120 works better than commonly used drug regimens for adults with relapsed or refractory multiple myeloma.

  Recruiting at 40 sites Phase 3 AstraZeneca · Gilbert, Arizona and 142 other locations · NCT07391657

• How a single ALPL gene change affects hypophosphatasia over time in Russia

  This observational study will follow children and adults with hypophosphatasia who carry one ALPL gene variant to see how their symptoms and health change during routine care in Russia.

  Recruiting at 3 sites AstraZeneca · Moscow and 3 other locations · NCT07390240

• Tezepelumab to reduce maintenance medication in people with severe asthma

  This will test whether people aged 12–80 with severe asthma in China who start tezepelumab can safely reduce their regular maintenance medicines while keeping asthma controlled.

  Recruiting at 59 sites Phase 3 AstraZeneca · Beijing and 74 other locations · NCT07363642

• Treatment patterns for managing high blood pressure in Brazil's public primary care system

  This project uses past medical records to see how adults with high blood pressure are treated in Brazil's public primary care system.

  Recruiting AstraZeneca · Florianópolis · NCT07361276

• Prophylaxis for Dato-DXd–Related Stomatitis in Breast Cancer and EGFR-MM NSCLC

  This study tests whether using dexamethasone mouthwash can prevent mouth sores caused by Dato-DXd in adults with certain breast cancer or EGFR-mutated NSCLC.

  Recruiting at 22 sites Phase 4 AstraZeneca · Tucson, Arizona and 40 other locations · NCT07357597

• Single-dose capivasertib testing in people with moderate liver impairment

  This trial will test how a single oral dose of capivasertib is processed and tolerated in adults with moderate liver impairment compared with people who have normal liver function.

  Recruiting at 2 sites Phase 1 AstraZeneca · Rialto, California and 1 other locations · NCT07343960

• Anifrolumab to achieve LLDAS5 in people with systemic lupus erythematosus

  This study tests whether anifrolumab helps people with systemic lupus erythematosus reach and keep low disease activity while staying on 5 mg/day or less of corticosteroids.

  Recruiting at 14 sites AstraZeneca · Monserrato, CA and 21 other locations · NCT07330245

• Treatment and outcomes for early-stage non-small cell lung cancer in China

  This chart review will look at treatment choices, biomarker testing, and outcomes for adults diagnosed with stage I–III non-small cell lung cancer in China.

  Recruiting AstraZeneca · Beijing · NCT07316062

• Checking for airflow limitation in smokers attending cardiology clinics

  This project will test how common airflow limitation is among people aged 40 and older with at least 10 pack‑years of smoking who visit cardiology clinics in Turkey.

  Recruiting at 2 sites AstraZeneca · Ankara and 1 other locations · NCT07315958

• COPD patients with frequent flare-ups in Moscow

  We will collect medical history and treatment details to see if real-world care relates to outcomes for adults in Moscow with moderate-to-very severe COPD who have frequent flare-ups.

  Recruiting AstraZeneca · Moscow · NCT07307781

• AZD0120 CD19/BCMA CAR T-cell therapy for systemic sclerosis, inflammatory myopathies, and difficult-to-treat rheumatoid arthritis

  This trial will try a dual-targeting CD19/BCMA CAR T-cell treatment (AZD0120) in adults with systemic sclerosis, idiopathic inflammatory myopathies, or difficult-to-treat rheumatoid arthritis to see if it is safe and well tolerated.

  Recruiting at 5 sites Phase 1/2 AstraZeneca · Tucson, Arizona and 26 other locations · NCT07295847

• Osimertinib before radiation and as maintenance for chemo-ineligible Stage III EGFR‑mutant unresectable NSCLC

  This phase 2 trial will test whether giving osimertinib before definitive radiation and continuing it afterward helps adults with Stage III unresectable EGFR‑mutant NSCLC who can't or won't have chemotherapy.

  Recruiting at 18 sites Phase 2 AstraZeneca · Beijing and 19 other locations · NCT07295821

• Datopotamab deruxtecan versus docetaxel for previously treated TROP2-positive advanced non-squamous NSCLC

  This trial tests whether datopotamab deruxtecan works better than docetaxel for people with TROP2-positive advanced or metastatic non-squamous NSCLC who have already received prior therapy and do not have actionable genomic alterations.

  Recruiting at 182 sites Phase 3 AstraZeneca · Chandler, Arizona and 205 other locations · NCT07291037

• AZD3974 safety and pharmacokinetics in healthy adults

  This trial will test whether AZD3974 is safe and well tolerated and how the body absorbs and clears it in healthy adults, including people of Japanese and Chinese descent, using single and multiple ascending oral doses and a food-effect check.

  Recruiting at 2 sites Phase 1 AstraZeneca · Glendale, California and 1 other locations · NCT07290283

• Acalabrutinib for CLL in routine care in Belarus

  This project will see how well acalabrutinib works and how safe it is for adults with chronic lymphocytic leukemia treated in routine clinical practice in Belarus.

  Recruiting at 3 sites AstraZeneca · Grodno and 3 other locations · NCT07288515

• Preventing recurrent C. difficile infection with the AZD5148 antibody

  This will try a single dose of the antibody AZD5148 versus placebo to see if it prevents repeat C. difficile infections in adults being treated for a current infection.

  Recruiting at 95 sites Phase 2 AstraZeneca · Phoenix, Arizona and 116 other locations · NCT07285213

• Osimertinib Plus Chemotherapy After Distant Recurrence in EGFRm NSCLC

  This trial tests combining osimertinib with chemotherapy for patients whose non-small cell lung cancer with EGFR mutations has recurred after prior osimertinib in the adjuvant setting.

  Recruiting at 22 sites Phase 4 AstraZeneca · Beijing and 31 other locations · NCT07279935

• AZD1163 treatment for adults with rheumatoid arthritis

  This will test whether injections of AZD1163, given with standard rheumatoid arthritis medicines, help adults with moderately-to-severely active, ACPA-positive RA.

  Recruiting at 117 sites Phase 2 AstraZeneca · Glendale, Arizona and 146 other locations · NCT07276581

• Treatment approaches for AChR-antibody positive generalized myasthenia gravis in Russia.

  This project will look at which treatments adults in Russia with AChR-antibody positive generalized myasthenia gravis receive and how their symptoms and hospitalizations change over time.

  Recruiting at 7 sites AstraZeneca · Kazan' and 6 other locations · NCT07247279

• Using oscillometry and FeNO to improve primary care diagnosis of asthma and COPD

  This study will test whether oscillometry and FeNO measurements help primary care doctors more accurately diagnose asthma and COPD in adults with suspected symptoms.

  Recruiting at 3 sites AstraZeneca · Buenos Aires and 11 other locations · NCT07245576

• AZD4063 for PLN R14del dilated cardiomyopathy.

  This study will test whether AZD4063 is safe and how the body processes it in adults with PLN R14del dilated cardiomyopathy.

  Recruiting at 4 sites Phase 1 AstraZeneca · Amsterdam and 3 other locations · NCT07241104

• AZD1613 safety and how the body handles it in adults with ADPKD

  We will test whether AZD1613 given under the skin or into a vein is safe and how the body processes it in adults with ADPKD who have eGFR between 45 and 90 mL/min/1.73m2.

  Recruiting at 10 sites Phase 1 AstraZeneca · Birmingham, Alabama and 14 other locations · NCT07228364

• AZD0120 CAR T-cell therapy for adults with multiple sclerosis

  This trial will test whether AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, is safe and tolerable in adults with relapsing or progressive multiple sclerosis.

  Recruiting at 7 sites Phase 1 AstraZeneca · Tucson, Arizona and 18 other locations · NCT07224373

• How common NF1 is in Egypt and how it progresses and is treated

  This project will look at people in Egypt with neurofibromatosis type 1 to see how common it is, what symptoms they have, how it changes over time, and how it is managed.

  Recruiting at 5 sites AstraZeneca · Al Mansurah and 8 other locations · NCT07221331

• Rilvegostomig or durvalumab with gemcitabine–cisplatin for first-line biliary tract cancer

  This compares rilvegostomig plus gemcitabine–cisplatin to durvalumab plus gemcitabine–cisplatin as first treatment for people with advanced biliary tract cancer.

  Recruiting at 153 sites Phase 3 AstraZeneca · Birmingham, Alabama and 182 other locations · NCT07221253

• AZD5335 versus mirvetuximab or chemotherapy for FRα-high and FRα-low platinum-resistant ovarian, fallopian tube, or peritoneal cancer

  This will test whether AZD5335 works better than mirvetuximab for FRα-high tumors or better than single-agent chemotherapy for FRα-low tumors in women with high-grade, platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.

  Recruiting at 95 sites Phase 3 AstraZeneca · Birmingham, Alabama and 298 other locations · NCT07218809

• AZD4144 for sepsis-associated acute kidney injury

  This will test whether IV AZD4144 given once daily can help adults with sepsis who recently developed acute kidney injury.

  Recruiting at 48 sites Phase 2 AstraZeneca · Phoenix, Arizona and 73 other locations · NCT07215702

• AZD0486 with short-course R-mini-CHOP for older or unfit people with large B‑cell lymphoma

  This tests whether two cycles of R-mini-CHOP followed by AZD0486 work as well and cause fewer side effects than six cycles of R-mini-CHOP for people aged 80+ or 65–79 who are unfit with newly diagnosed large B‑cell lymphoma.

  Recruiting at 29 sites Phase 3 AstraZeneca · Clayton and 81 other locations · NCT07215585

• Real-world benralizumab treatment for adults with severe eosinophilic asthma in Italy

  This study will test whether benralizumab helps adults with severe eosinophilic asthma reach partial or complete clinical remission during routine care in Italy.

  Recruiting at 12 sites AstraZeneca · Salerno, Battipaglia and 27 other locations · NCT07214753

• Dato-DXd for inoperable or metastatic HR-positive, HER2 IHC 0 breast cancer

  This trial tests Dato-DXd given every 3 weeks before chemotherapy to see if it helps people with metastatic HR-positive, HER2 IHC 0 breast cancer who are no longer responding to endocrine therapy.

  Recruiting at 39 sites Phase 3 AstraZeneca · Largo, Florida and 39 other locations · NCT07205822

• Eplontersen exposure during pregnancy and breastfeeding: outcomes

  This project collects reports to see if exposure to eplontersen during pregnancy or breastfeeding affects mothers, fetuses, or infants with transthyretin amyloidosis.

  Recruiting AstraZeneca · Frankfurt · NCT07205666

• Surovatamig injections for adults with rheumatoid arthritis or lupus

  This study will try giving subcutaneous surovatamig to adults with rheumatoid arthritis or lupus to see if it is safe and how the body processes it.

  Recruiting at 26 sites Phase 1 AstraZeneca · Birmingham, Alabama and 34 other locations · NCT07201558

• AZD6621 for adult men with metastatic prostate cancer.

  This study will try an experimental drug called AZD6621 in adult men with metastatic prostate cancer to see if it is safe, how it moves through the body, and whether it can help control the cancer.

  Recruiting at 15 sites Phase 1/2 AstraZeneca · Orlando, Florida and 25 other locations · NCT07192614

• AZD0516 alone and with AZD9574 for metastatic prostate cancer

  This trial will test AZD0516, alone and combined with AZD9574, to see if it is safe and helps people with metastatic prostate cancer who have castrate-level testosterone.

  Recruiting at 23 sites Phase 1/2 AstraZeneca · Fayetteville, Arkansas and 51 other locations · NCT07181161

• Subcutaneous rilvegostomig with hyaluronidase for adults with advanced solid tumors

  This trial will test whether subcutaneous rilvegostomig given with recombinant human hyaluronidase produces drug levels similar to the intravenous form in adults with advanced solid tumors who have already received standard treatments and are suitable for immuno-oncology monotherapy.

  Recruiting at 8 sites Phase 1 AstraZeneca · Huntersville, North Carolina and 10 other locations · NCT07161414

• Durvalumab consolidation after chemoradiation for limited-stage small-cell lung cancer in China

  This project will test durvalumab given after chemoradiation in people with limited‑stage small‑cell lung cancer who have not progressed, to see how well it works and how safe it is in routine care.

  Recruiting at 20 sites AstraZeneca · Beijing and 20 other locations · NCT07161388

• AZD3632, alone or with other anticancer agents, for advanced blood cancers driven by HOX overexpression

  This trial will test whether the oral drug AZD3632, given alone or with the antifungal posaconazole, is safe and helps control relapsed or refractory AML, ALL, or high-risk MDS that have KMT2A rearrangements, NPM1 mutations, or other genotypes causing HOX overexpression.

  Recruiting at 20 sites Phase 1/2 AstraZeneca · Decatur, Illinois and 29 other locations · NCT07155226

• LUNG-ROLL: Treatment patterns and costs for people with lung cancer in Canada

  This project looks at past health records to see how lung cancer is treated and what healthcare it uses for adults in Alberta and Ontario.

  Recruiting at 2 sites AstraZeneca · Calgary, Alberta and 1 other locations · NCT07143110

• Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors

  This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.

  Recruiting at 18 sites AstraZeneca · Birmingham, Alabama and 17 other locations · NCT07124000

• AZD4512 alone or with other medicines for relapsed or refractory B‑cell non‑Hodgkin lymphoma

  This trial will try AZD4512 by itself or with other cancer drugs to see if it helps adults whose B‑cell non‑Hodgkin lymphoma has relapsed or not responded after prior treatments.

  Recruiting at 16 sites Phase 1/2 AstraZeneca · Irvine, California and 22 other locations · NCT07123454

• Testing AZD6750 safety in adults with selected advanced or metastatic solid tumors

  This trial tests whether AZD6750, a CD8-guided IL-2 medicine given alone or with other cancer drugs, is safe and how it behaves in adults with certain advanced or metastatic solid tumors.

  Recruiting at 13 sites Phase 1/2 AstraZeneca · Grand Rapids, Michigan and 12 other locations · NCT07115043

• AZD4512 alone or with other cancer drugs for relapsed/refractory CD22-positive B‑cell ALL

  This trial will test whether AZD4512, given alone, is safe and can help adults and adolescents with relapsed or refractory CD22-positive B‑cell acute lymphoblastic leukemia.

  Recruiting at 21 sites Phase 1/2 AstraZeneca · Duarte, California and 26 other locations · NCT07109219

• First-line treatment choices and patient profiles in advanced non-small cell lung cancer

  This project will collect electronic medical record data from adults with advanced non‑small cell lung cancer starting first‑line treatment to see if real‑world care and biomarker use (like driver mutations and PD‑L1) match guideline recommendations.

  Recruiting at 2 sites AstraZeneca · Recife and 6 other locations · NCT07109154

• HER2 expression across Brazilian gynecologic cancers

  This will test HER2 protein levels in tumor samples from adults with gynecologic cancers treated at Oncoclínicas sites to see how often HER2 is highly expressed.

  Recruiting AstraZeneca · São Paulo · NCT07101081

• New drug combinations for advanced non-small cell lung cancer

  This Phase II platform tests several combinations of targeted antibodies and antibody‑drug conjugates for adults with advanced or metastatic non‑small cell lung cancer, with treatment arms matched to PD‑L1 status and genomic findings.

  Recruiting at 58 sites Phase 2 AstraZeneca · Santa Monica, California and 82 other locations · NCT07098338

• Clinical and demographic characteristics of adults with neurofibromatosis in Russia

  This project collects routine clinical and patient-reported information from adults in Russia who have neurofibromatosis with symptomatic plexiform neurofibromas to see how the condition affects their health and care.

  Recruiting at 16 sites AstraZeneca · Arkhangelsk and 15 other locations · NCT07088991

• IV AZD0292 for people 12+ with bronchiectasis and chronic Pseudomonas aeruginosa

  This will test whether IV AZD0292 can reduce lung exacerbations in people aged 12 and older who have bronchiectasis with chronic Pseudomonas aeruginosa colonization.

  Recruiting at 163 sites Phase 2 AstraZeneca · Orange, California and 185 other locations · NCT07088926

• AZD6793 for people with moderate to very severe COPD

  This trial will test three different doses of the oral medicine AZD6793 against a placebo in adults with moderate to very severe COPD to see if it improves symptoms and reduces flare-ups.

  Recruiting at 302 sites Phase 2 AstraZeneca · Birmingham, Alabama and 366 other locations · NCT07082738

• Budesonide/glycopyrronium/formoterol inhaler versus placebo for heart and lung function in COPD with hyperinflation

  We will test whether a combination inhaler (budesonide/glycopyrronium/formoterol) improves heart and lung function in people with COPD who have lung hyperinflation.

  Recruiting at 6 sites Phase 4 AstraZeneca · Ahrensburg and 6 other locations · NCT07073950

• AZD0120 treatment for adults with newly diagnosed or early relapsed multiple myeloma.

  This study will try AZD0120 in adults with newly diagnosed, early relapsed, or primary refractory multiple myeloma to see if it is safe and shows early signs of benefit.

  Recruiting at 9 sites Phase 1 AstraZeneca · Phoenix, Arizona and 12 other locations · NCT07073547

• AI screening tool using WhatsApp to predict genetic risk for breast cancer

  This project will test whether an AI-based WhatsApp virtual assistant can use family cancer history to predict which women referred for genetic evaluation have higher genetic risk for breast cancer.

  Recruiting AstraZeneca · Golania, Goiás and 2 other locations · NCT07070128

• One-year real-world outcomes with Breztri/Trixeo (BGF) in adults with moderate to severe COPD

  See how adults with moderate to severe COPD do over 12 months after starting Breztri/Trixeo (BGF) in routine care settings.

  Recruiting at 19 sites AstraZeneca · Buenos Aires and 35 other locations · NCT07069829

• Novel perioperative drug combinations for locally advanced resectable gastric and gastroesophageal junction adenocarcinoma

  This trial will test new drugs or drug combinations given before and around surgery for people with locally advanced, resectable stomach or gastroesophageal junction adenocarcinoma who haven't had prior treatment.

  Recruiting at 54 sites Phase 2 AstraZeneca · Newark, Delaware and 69 other locations · NCT07069712

• DLBCL in the MEA region: how patients are treated and access to new therapies

  This study looks at how people with diffuse large B-cell lymphoma are treated and how they can access newer therapies across MEA sites.

  Recruiting at 11 sites AstraZeneca · Al Mansurah and 20 other locations · NCT07065344

• AZD2962 (IRAK4 blocker) for relapsed MDS and dysplastic CMML

  This trial will test whether the oral drug AZD2962, which blocks IRAK4, is safe and can help adults with relapsed or refractory myelodysplastic syndromes (MDS) or dysplastic chronic myelomonocytic leukemia (CMML).

  Recruiting at 15 sites Phase 1 AstraZeneca · Miami, Florida and 20 other locations · NCT07064122

• Treatment choices and blood HRR gene testing in aggressive, high-volume metastatic hormone-sensitive prostate cancer in Russia

  See how treatment choices and blood-based HRR gene testing appear in men with aggressive, high-volume metastatic hormone-sensitive prostate cancer in the Russian Federation.

  Recruiting at 14 sites AstraZeneca · Arkhangelsk and 27 other locations · NCT07052578

• Anifrolumab Pregnancy Study in women with lupus

  This study looks at pregnancy outcomes in women with moderate to severe SLE who took anifrolumab during pregnancy and compares them to similar women who did not take the drug.

  Recruiting AstraZeneca · Cary, North Carolina · NCT07049653

• Puxitatug samrotecan versus chemotherapy for B7-H4–positive advanced endometrial cancer

  This trial will test whether puxitatug samrotecan helps people with B7‑H4–positive advanced or metastatic endometrial cancer live longer or keep their cancer from getting worse compared with standard chemotherapy after platinum and PD‑1/PD‑L1 treatment.

  Recruiting at 212 sites Phase 3 AstraZeneca · Tucson, Arizona and 319 other locations · NCT07044336

• Molecular profiling and first-line treatment patterns for advanced aggressive endometrial cancer in Russia

  This project will collect tumor molecular profiles and first-line treatment information from people in Russia with newly diagnosed advanced, aggressive endometrial cancer to see which molecular changes are common and how patients are being treated.

  Recruiting at 16 sites AstraZeneca · Arkhangelsk and 18 other locations · NCT07041606

• Treatment approaches and biomarker prevalence in bladder cancer in Russia

  This project tests how common HER2 and PD-L1 markers are at different stages of bladder cancer and records current treatment approaches in adults across Russia.

  Recruiting at 14 sites AstraZeneca · Arkhangelsk and 19 other locations · NCT07038928

• Acalabrutinib plus R-CHOP as first-line treatment for mantle cell lymphoma in Spain

  This test will see if adding acalabrutinib to standard R-CHOP helps adults in Spain with newly diagnosed mantle cell lymphoma.

  Recruiting at 21 sites Phase 2 AstraZeneca · A Coruña and 21 other locations · NCT07029737

• AZD4248 in healthy adults and people with diabetic chronic kidney disease

  This project will test whether single and multiple doses of AZD4248 are safe and how the drug behaves in healthy adults and people with diabetic kidney disease, and will also see if home creatinine testing is practical.

  Recruiting at 4 sites Phase 1 AstraZeneca · Glendale, California and 4 other locations · NCT07024823

• Acalabrutinib and Venetoclax for relapsed CLL/SLL after initial BTKi+BCL2i response

  This trial tests a finite-duration combination of acalabrutinib and venetoclax in adults whose CLL or SLL has relapsed after a first-line BTKi+BCL2i therapy and who had at least 2 years of response.

  Recruiting at 16 sites Phase 2 AstraZeneca · Boston, Massachusetts and 46 other locations · NCT07024706

• AZD0780 to reduce major heart and blood vessel events in people with or at high risk for atherosclerotic cardiovascular disease.

  This trial tests whether the oral PCSK9 inhibitor AZD0780 can lower the risk of major heart and vascular events in adults with prior ASCVD or who are at high risk for a first ASCVD event.

  Recruiting at 1106 sites Phase 3 AstraZeneca · Athens, Alabama and 1451 other locations · NCT07000357

• Anifrolumab and risk of cancers and serious infections in SLE

  This project will see if adults with moderate-to-severe SLE who start anifrolumab have different rates of cancers and serious infections than similar patients receiving standard care.

  Recruiting at 4 sites AstraZeneca · Copenhagen and 3 other locations · NCT07000110

• Platform of new drug combinations for advanced non-small cell lung cancer

  This will test rilvegostomig given with platinum-based chemotherapy, with or without ramucirumab, in people with advanced or metastatic non-small cell lung cancer whose tumors have PD-L1 TPS ≥1%.

  Recruiting at 57 sites Phase 1/2 AstraZeneca · Phoenix, Arizona and 102 other locations · NCT06996782

• Durvalumab with or without Olaparib for people with endometrial cancer in Korea

  This study will see if Durvalumab, with or without Olaparib, is safe and works for people in Korea who are prescribed these drugs for endometrial cancer as part of routine care.

  Recruiting AstraZeneca · Seoul · NCT06995833

• New treatment options for advanced endometrial cancer

  This study is testing a new combination of treatments for advanced endometrial cancer to see if it can help patients live longer without their cancer getting worse compared to standard chemotherapy.

  Recruiting at 205 sites Phase 3 AstraZeneca · Tucson, Arizona and 256 other locations · NCT06989112

• AZD4954 safety and dosing in adults with or without high lipoprotein(a) and in people with dyslipidemia

  This trial will test single and repeated doses of AZD4954 in healthy adults and adults with high Lp(a) or dyslipidemia to see how safe the drug is and how it behaves in the body.

  Recruiting at 6 sites Phase 1 AstraZeneca · Glendale, California and 5 other locations · NCT06980428

• Using durvalumab with chemotherapy for muscle-invasive bladder cancer

  This study is testing if adding a new immune therapy called durvalumab to standard chemotherapy can help people with muscle-invasive bladder cancer before they have surgery.

  Recruiting at 48 sites Phase 2 AstraZeneca · Chermside and 58 other locations · NCT06960577

• Adding saruparib to radiation and hormone therapy for high-risk prostate cancer with a BRCA mutation

  This trial will test whether adding saruparib to standard radiation and androgen‑deprivation therapy helps men with high‑risk localized or locally advanced prostate cancer who have a BRCA1 or BRCA2 mutation stay metastasis‑free longer.

  Recruiting at 282 sites Phase 3 AstraZeneca · Phoenix, Arizona and 345 other locations · NCT06952803

Showing recruiting studies first, then the newest. Describe your situation to find the ones that fit you.

Quick answers

How many clinical trials run by AstraZeneca are recruiting right now?

244, as of November 12, 2026. 3 of them were first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 81 countries. The most sites are in United States (136 trials), China (120 trials), Spain (104 trials), United Kingdom (95 trials), Germany (95 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 72, Phase 2: 26, Phase 1/2: 26, Phase 1: 24. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →